Form 4: PLUS THERAPEUTICS CEO Awarded Significant Equity

PLUS THERAPEUTICS, INC. CEO Marc H. Hedrick received 2,419,582 Restricted Stock Units and 2,419,582 stock options, aligning executive incentives with long-term company performance.

Summary

• Marc H. Hedrick, Chief Executive Officer and Director of PLUS THERAPEUTICS, INC. (PSTV), was awarded 2,419,582 Restricted Stock Units (RSUs) and 2,419,582 stock options.
• The RSUs represent a contingent right to receive one share of Common Stock each, with a transaction price of $0.
• RSUs will vest ratably over twelve quarters in substantially equal 1/12th increments, commencing April 1, 2026.
• The stock options have an exercise price of $0.28 per share.
• Stock options will vest over four years in substantially equal 1/48th increments on each monthly anniversary of the issuance date.
• Options also vest upon a change of control, as per the Optionee's employment agreement, and expire on February 24, 2036.
• Following these transactions, Mr. Hedrick beneficially owns 4,016,388 Restricted Stock Units and 2,419,582 Stock Options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it strengthens the alignment between the CEO's financial interests and the long-term performance of PLUS THERAPEUTICS, which is generally favorable for shareholders.

Positives

• The equity awards align the Chief Executive Officer's interests directly with long-term shareholder value creation.
• The multi-year vesting schedules for both RSUs (3 years) and stock options (4 years) encourage sustained performance and retention of key leadership.
• The change of control vesting clause for options provides an incentive for successful strategic transactions.

Future Outlook

The vesting schedules for the awarded Restricted Stock Units and stock options extend several years into the future, indicating a long-term commitment from the CEO and aligning his incentives with the company's sustained performance and growth.

Industry Context

StockSavvy.ai notes that significant equity awards to a Chief Executive Officer, particularly with multi-year vesting schedules, are a common practice in the biotechnology and pharmaceutical industries. This approach is designed to incentivize long-term strategic execution and align executive compensation with shareholder returns, especially in companies like PLUS THERAPEUTICS that are often focused on long-term drug development cycles.

Comparison to Industry Standards

• The grant of Restricted Stock Units and stock options is a standard component of executive compensation packages across various industries, including biotech.
• The vesting periods of three years for RSUs and four years for options are typical for executive equity awards, comparable to practices at companies such as Moderna (MRNA) or BioNTech (BNTX) for their senior leadership, aiming to ensure long-term commitment and performance.
• The inclusion of a change of control vesting clause for options is also a common feature, designed to protect executive interests during M&A activities and ensure continuity during potential transitions.

Stakeholder Impact

• Shareholders: Potentially positive, as the CEO's long-term incentives are aligned with increasing shareholder value.
• Employees: No direct impact mentioned, but strong leadership incentives can indirectly benefit overall company stability and growth.

Next Steps

• Vesting of Restricted Stock Units will commence on April 1, 2026, and continue quarterly over twelve quarters.
• Vesting of Stock Options will occur monthly over four years, starting from the issuance date.

Key Dates

Keywords

PLUS THERAPEUTICS, PSTV, Marc H. Hedrick, CEO, Director, Restricted Stock Units, RSU, Stock Options, Equity Award, Insider Transaction, Executive Compensation, SEC Form 4, Beneficial Ownership